Stock Yards Bank & Trust Co Boosted Johnson & Johnson (JNJ) Stake By $2.58 Million; IRADIMED (IRMD)’s Sentiment Is 2.57

April 20, 2018 - By Hugh Holland

IRadimed Corporation (NASDAQ:IRMD) Logo

IRADIMED CORP (IRMD) investors sentiment increased to 2.57 in 2017 Q4. It’s up 2.15, from 0.42 in 2017Q3. The ratio increased, as 18 investment managers increased and started new stock positions, while 7 reduced and sold holdings in IRADIMED CORP. The investment managers in our database now hold: 1.61 million shares, up from 1.46 million shares in 2017Q3. Also, the number of investment managers holding IRADIMED CORP in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 6 Increased: 10 New Position: 8.

Stock Yards Bank & Trust Co increased Johnson & Johnson (JNJ) stake by 13.74% reported in 2017Q4 SEC filing. Stock Yards Bank & Trust Co acquired 18,540 shares as Johnson & Johnson (JNJ)’s stock declined 9.21%. The Stock Yards Bank & Trust Co holds 153,470 shares with $21.44M value, up from 134,930 last quarter. Johnson & Johnson now has $342.17 billion valuation. The stock decreased 0.13% or $0.17 during the last trading session, reaching $127.55. About 5.96M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since April 20, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.

Analysts await IRadimed Corporation (NASDAQ:IRMD) to report earnings on April, 27. They expect $0.04 EPS, up 300.00% or $0.06 from last year’s $-0.02 per share. IRMD’s profit will be $424,183 for 98.44 P/E if the $0.04 EPS becomes a reality. After $0.06 actual EPS reported by IRadimed Corporation for the previous quarter, Wall Street now forecasts -33.33% negative EPS growth.

Since January 1, 0001, it had 1 insider purchase, and 1 insider sale for $401,176 activity.

The stock increased 0.32% or $0.05 during the last trading session, reaching $15.75. About 3,062 shares traded. IRadimed Corporation (IRMD) has risen 68.64% since April 20, 2017 and is uptrending. It has outperformed by 57.09% the S&P500.

Iradimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging compatible products, and related accessories and services in the United States and internationally. The company has market cap of $167.02 million. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. It has a 393.75 P/E ratio. The firm also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories; iMagox MRI pulse oximeter; and iMagox MRI oximeter remote and display products.

Menta Capital Llc holds 0.2% of its portfolio in IRadimed Corporation for 66,976 shares. Granite Investment Partners Llc owns 99,238 shares or 0.09% of their US portfolio. Moreover, Mondrian Investment Partners Ltd has 0.08% invested in the company for 206,547 shares. The Pennsylvania-based Connors Investor Services Inc has invested 0.07% in the stock. Eam Investors Llc, a California-based fund reported 30,141 shares.

Stock Yards Bank & Trust Co decreased Ventas Inc (NYSE:VTR) stake by 131,245 shares to 48,518 valued at $2.91 million in 2017Q4. It also reduced Blackrock Inc (NYSE:BLK) stake by 665 shares and now owns 40,170 shares. Paychex Inc (NASDAQ:PAYX) was reduced too.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson had 95 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Hold” on Tuesday, March 15. Jefferies maintained the shares of JNJ in report on Wednesday, October 18 with “Buy” rating. The stock has “Sell” rating by Standpoint Research on Friday, May 20. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Monday, October 23 by Citigroup. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, January 25. The firm has “Outperform” rating by Cowen & Co given on Tuesday, August 25. The rating was maintained by Jefferies with “Buy” on Friday, April 13. BMO Capital Markets maintained Johnson & Johnson (NYSE:JNJ) on Friday, June 2 with “Buy” rating. As per Thursday, April 12, the company rating was upgraded by Credit Suisse. BMO Capital Markets maintained it with “Buy” rating and $14500 target in Tuesday, July 18 report.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News